All In Biotech

Drug Trial Radar · NCT02004704

A Long-Term Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency

A Long-Term Study to Assess the Ongoing Safety and Efficacy of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency

Last checked: Nov 20, 2026Latest source record: Jul 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

25

Actual

Start

Dec 4, 2013

Primary completion

Sep 6, 2023

Study completion Sep 6, 2023

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Dec 9, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study was to obtain data regarding the safety of olipudase alfa in participants with acid sphingomyelinase deficiency (ASMD) who were exposed to long term treatment with olipudase alfa. The secondary objectives of this study were to obtain data regarding the efficacy of olipudase alfa and to characterize olipudase alfa pharmacodynamics (PD) and pharmacokinetics (PK) following long-term administration.

Conditions

  • Sphingomyelin Lipidosis

Interventions

  • GZ402665Drug

    Pharmaceutical form: Powder for concentrate for solution for infusion Route of administration: intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (TESAEs) and Adverse Events of Special Interest (AESIs) Except Infusion-Associated Reactions (IARs)Time frame: From the signature of informed consent up to 9 years or until olipudase alfa was commercially accessible, whichever came first
  2. Number of Participants With IARsTime frame: From the signature of informed consent up to 9 years or until olipudase alfa was commercially accessible, whichever came first
  3. For Adults: Number of Participants With Abnormality in Complete Physical Examinations Including Abbreviated Physical ExamTime frame: Baseline (Day 1 of original study), Month 78
  4. For Pediatrics: Number of Participants With Abnormality in Complete Physical Examinations Including Abbreviated Physical ExamTime frame: Baseline (Day 1 of original study), Month 84
  5. For Adults: Number of Participants With Abnormality in Extended Neurological ExaminationsTime frame: Baseline (Day 1 of original study), Month 78
  6. For Pediatrics: Number of Participants With Abnormality in Extended Neurological ExaminationsTime frame: Baseline (Day 1 of original study), Month 84
  7. Number of Participants With Potentially Clinically Significant Abnormalities (PCSA) in Vital SignsTime frame: Baseline (Day 1 of original study) up to 9 years or until olipudase alfa was commercially accessible, whichever came first
  8. Number of Participants With PCSA in Clinical Chemistry ParametersTime frame: Baseline (Day 1 of original study) up to 9 years or until olipudase alfa was commercially accessible, whichever came first
  9. Number of Participants With PCSA in Liver Function TestsTime frame: Baseline (Day 1 of original study) up to 9 years or until olipudase alfa was commercially accessible, whichever came first
  10. Number of Participants With PCSA in Hematology ParametersTime frame: Baseline (Day 1 of original study) up to 9 years or until olipudase alfa was commercially accessible, whichever came first
  11. Number of Participants With PCSA in Electrocardiogram (ECG)Time frame: Baseline (Day 1 of original study) up to 9 years or until olipudase alfa was commercially accessible, whichever came first
  12. For Adults: Percent Change From Baseline in Pre-Infusion Plasma Ceramide at Month 90Time frame: Baseline (Day 1 of original study) and Month 90 (pre-infusion)
  13. For Pediatrics: Percent Change From Baseline in Pre-Infusion Plasma Ceramide at Month 66Time frame: Baseline (Day 1 of original study) and Month 66 (pre-infusion)
  14. Participants From Adult Study DFI13412: Number of Participants With Abnormal Liver BiopsyTime frame: Baseline (Day 1 of original study) and Month 36
  15. Participants From Pediatric Study DFI13803: Number of Participants With Abnormalities in Liver Ultrasound DopplerTime frame: Baseline (Day 1 of original study), Week 2 and Months 12, 18 and 24
  16. Number of Participants With Anti-Drug Antibodies (ADA) Against Olipudase AlfaTime frame: Baseline (Day 1 of original study) up to 9 years or until olipudase alfa was commercially accessible, whichever came first

Locations

9 sites in 7 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 840001

    New York, New York

  • Investigational Site Number 056001

    Leuven, Belgium

  • Investigational Site Number 076001

    Porto Alegre, Brazil

  • Investigational Site Number 250002

    Bron, France

  • Investigational Site Number 276002

    Hochheim am Main, Germany

  • Investigational Site Number 380002

    Sassari, Italy

  • Investigational Site Number 380001

    Udine, Italy

  • Investigational Site Number 826001

    London, United Kingdom

  • Investigational Site Number 826002

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.